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Abstract
The idea that the environmental toxin β-N-methylamino-L-alanine
(BMAA) is involved in neurodegenerative diseases on Guam has risen and
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fallen over the years. The theory has gained greater interest with recent
reports that BMAA is biomagnified, is widely distributed around the planet,
and is present in the brains of Alzheimer’s patients in Canada. We provide two
important new findings. First, we show that BMAA at concentrations as low as
10 µM can potentiate neuronal injury induced by other insults. This is the first
evidence that BMAA at concentrations below the mM range can enhance
death of cortical neurons and illustrates potential synergistic effects of
environmental toxins with underlying neurological conditions. Second, we
show that the mechanism of BMAA toxicity is three fold: it is an agonist for
NMDA and mGluR5 receptors, and induces oxidative stress. The results
provide further support for the hypothesis that BMAA plays a role in
neurodegenerative diseases.

Keywords: BMAA, Alzheimer’s disease, oxidative stress, apoptosis,
necrosis, NMDA

Introduction
The hypothesis that BMAA is involved in the development of
amyotrophic lateral sclerosis/Parkinson-dementia complex (ALS/PDC)
on Guam, locally known as Lytico-Bodig, has risen and fallen since its
initial proposal in 1987 (Spencer et al., 1987; Cox and Sacks, 2002). A
major criticism regarding the hypothesis is that high BMAA
concentrations are required to induce behavioral abnormalities and
neuronal death. The initial proposal was that the native Chamorro
people of Guam were exposed to BMAA through the consumption of
cycad seeds containing BMAA. However, it was determined that the
Chamorros thoroughly wash the cycad seeds leading to very low levels
of BMAA being consumed (Duncan et al., 1990). Recent reports have
brought the BMAA hypothesis back into prominence. First, it was
shown that BMAA is biomagnified as it travels through the food chain
from the cyanobacteria symbionts on cycad plants, to the fruit bats
that forage on the cycad seeds, to the people who eat the bats (Cox et
al., 2003). This is not the first instance of biomagnification of an
excitotoxin; the consumption of shellfish that feed on algae that
produce the excitotoxin domoic acid has led to human neurological
deficits (Perl et al., 1990). Second, BMAA can become proteinassociated, leading to further increases in human BMAA levels and
providing a potential mechanism for slow release (Murch et al., 2004).
There is also previous evidence that many non-protein amino acids can
become protein-associated (Rosenthal, 1977). The slow release of
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BMAA provides a possible explanation for the delayed onset of
ALS/PDC following the time of probable BMAA consumption (Ince and
Codd, 2005). Third, BMAA has been found in cyanobacteria present
throughout the world (Cox, 2005), suggesting that BMAA may be of
concern not only for specific groups of Pacific Islanders, but for a much
larger population. This point was further emphasized by the finding
that BMAA is found not only in brain samples of ALS/PDC patients from
Guam, but also in Alzheimer’s disease patients from Canada (Murch et
al., 2004). Questions regarding the BMAA hypothesis still remain. For
example, a recent report found no evidence of BMAA in brains of
patients with ALS/PDC or Alzheimer’s disease (Montine et al., 2005). A
number of technical differences may account for the differing results.
Murch et al. (2004) used paraformaldehyde fixed tissue and performed
an acid hydrolysis to release protein associated BMAA. While they
found some free BMAA, the large majority of BMAA was protein
associated. Montine et al. (2005) used non-fixed brain tissue.
However, they did not perform an acid hydrolysis. A definitive answer
will clearly require additional studies.
A critical problem with the BMAA theory at present is that even
though biomagnification of BMAA in the environment can occur it is
still not clear that high enough concentrations are reached to cause
toxicity. Studies in cortical cell culture have shown that very high
BMAA concentrations (1 – 3 mM) are required to induce neuronal
death (Ross et al., 1987; Weiss and Choi, 1988; Weiss et al., 1989).
The purpose of the current studies was to test whether lower
concentrations of BMAA could potentiate low level toxicity induced by
other insults. The idea being that while BMAA alone may not cause
neurological deficits, the combination of low level BMAA and naturally
occurring insults, or genetic predisposition to various diseases, may
lead to the expression of neurological diseases.

Material and Methods
Materials
Timed pregnant Swiss Webster mice were obtained from Charles
River Laboratories (Wilmington, DE, USA). 45Ca++ was from
PerkinElmer Life and Analytical Sciences (Boston, MA). 5-(and –6)-
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carboxy-2’7’-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA)
was from Molecular Probes (Eugene, OR). All other chemicals were
obtained from Sigma (St. Louis, MO).

Cortical cell cultures
Timed pregnant Swiss Webster mice were obtained from Charles
River Laboratories (Wilmington, DE, USA). Mixed cortical cell cultures
containing neurons and astrocytes were prepared from fetal (15–16
day gestation) mice as previously described (Lobner, 2000).
Dissociated cortical cells were plated on 24 well plates coated with
poly-D-lysine and laminin in Eagles’ Minimal Essential Medium (MEM,
Earle’s salts, supplied glutamine-free) supplemented with 5% heatinactivated horse serum, 5% fetal bovine serum, 2 mM glutamine, 26
mM NaHCO3 and glucose (total 21 mM). Cultures were maintained in
humidified 5% CO2 incubators at 37°C. The mice were handled in
accordance with a protocol approved by the institutional animal care
committee.

Induction of neuronal death
All experiments were performed on mixed cultures 13–15 days
in vitro (DIV). Toxicity was induced by exposure to the toxic agents for
24 hours in media as described for plating except without serum.
Amyloid-β was prepared as a 1 mM peptide stock solution in sterile
distilled water and maintained for 3 days at room temperature to allow
polymerization (Yin et al., 2006). In kainate, Fe, and BSO toxicity
experiments, 1 µM MK-801 was added to eliminate the effect of
endogenously released glutamate acting on NMDA receptors. This
procedure allows for the study of pure AMPA/kainate receptor
mediated toxicity and pure oxidative stress induced toxicity without
the confounding effects of NMDA receptor activation (Dugan et al.,
1997). All exposure media contained 20–26 mM NaHCO3, as it has
been shown previously that HCO3− is required for expression of NMDA
receptor mediated BMAA toxicity (Weiss and Choi, 1988).
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LDH Release
Cell death was assessed in mixed cultures by the measurement
of lactate dehydrogenase (LDH), released from damaged or destroyed
cells, in the extracellular fluid 24 hours after the beginning of the
insult. Blank LDH levels were subtracted from insult LDH values and
results normalized to 100% neuronal death caused by 500 µM NMDA.
Control experiments have shown previously that the efflux of LDH
occurring from either necrotic or apoptotic cells is proportional to the
number of cells damaged or destroyed (Koh and Choi, 1987; Lobner,
2000). In none of the conditions in the studies presented here was
there any evidence of glial cell death observed (assessed by trypan
blue staining). Therefore results are presented as percent neuronal
death.
45

Ca++ accumulation

Mixed cortical cultures were exposed to BMAA or NMDA in the
presence of 45Ca++ (final activity, 2 µCi/ml) for 1 hour (Harley et al.,
1993). There was less than 10% neuronal death after the 1 hour
exposure to the toxins as measured by LDH release. Exposure was
terminated by thoroughly washing the cells of extracellular 45Ca++.
Subsequently, the extracellular media was removed, cells were lysed
with 1% sodium dodecyl sulfate, and an aliquot was added to
scintillation fluid for counting. Values were normalized to control 45Ca++
uptake (60 minute exposure to 45Ca++ without BMAA or NMDA).

Electrophysiological recording
Whole-cell patch-clamp recording was performed as previously
described (Ren et al., 2003). Briefly, gigaohm seals were obtained with
patch electrodes (series resistance: 2 – 10 MΩ, compensation 80%),
and cells were voltage-clamped at −50 mV and superfused in
extracellular solution containing (in mM): NaCl, 150; KCl, 5; CaCl2,
0.2; HEPES, 10; NaHCO3, 20; glucose, 10; and sucrose, 10; pH 7.4.
The patch pipet solution contained (in mM): CsCl, 140; Mg4ATP, 2;
BAPTA, 10; HEPES, 10; NaHCO3, 20; pH 7.4. Drugs were prepared
daily in extracellular solution. Drug solutions were applied to cells from
a multibarrel array of 600 µm i.d. square glass tubing held in a stepper
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motor-driven rapid solution exchange apparatus (Fast-step, Warner
Instrument Co.). Data were filtered at 2 kHz (low-pass, eight-pole
Bessel) and acquired at 5 – 10 kHz on a computer using a DigiData
interface and pClamp software (Axon Instruments).

Assay of intracellular oxidative stress
Oxidative stress was assayed by measuring dichlorofluorescein
oxidation using a fluorescent plate reader following a modification of a
previous method (Wang and Joseph, 1999). Cultures were exposed to
3 mM BMAA for 3 hours in the presence of 5-(and –6)-carboxy-2’7’dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (10 µM).
There was less than 10% neuronal death after the 3 hour exposure to
BMAA as measured by LDH release (8.2 ± 1.8 % neuronal death
measured at the end of 3 hour exposure to 3 mM BMAA). The carboxyH2DCFDA is de-esterfied within cells to form a free acid that can then
be oxidized to the fluorescent 2’7’-dichlorofluorescein (DCF). After the
exposure to carboxy-H2DCFDA, cultures were washed 3 times with
culture media lacking serum. Fluorescence was then measured using a
Fluoroskan Ascent fluorescence plate reader (ThermoLabsystems). The
excitation filter was set at 485 nm and emission filter at 538 nm.
Background fluorescence (no carboxy-H2DCFDA added) was subtracted
and the results normalized to control conditions (carboxy-H2DCFDA
added, but no BMAA exposure).

Results
Low concentration of BMAA potentiates effects of other
neurotoxins
Previous studies have found that BMAA is neurotoxic both in
vivo (Spencer et al., 1987) and in vitro (Ross et al., 1987; Weiss and
Choi, 1988; Weiss et al., 1989; Zeevalk and Nicklas, 1989), but that
induction of neuronal death by BMAA requires high concentrations. We
repeated these studies in cortical cultures and found similar results,
with no significant toxicity occurring until a BMAA concentration of 1
mM (Figure 1). Table 1 shows the effects of BMAA concentrations of
10, 50 and 100 µM, both alone, and in combination with insults that
induce low levels of neuronal death. The results indicate that BMAA at
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these concentrations causes no toxicity by itself, but it does potentiate
a number of types of injury. Specifically, at 100 µM or less, it
potentiated N-methyl-D-aspartate (NMDA), iron (Fe), buthionine
sulfoximine (BSO), amyloid-β, and 1-methyl-4-phenylpyridinium ion
(MPP+) toxicity. The lowest concentration that caused an effect was 10
µM BMAA, which caused potentiation of amyloid-β and MPP+ toxicity.

Figure 1 BMAA alone does not induce significant toxicity until a concentration of 1
mM. Bars show % neuronal cell death (mean ± SEM, n=8–16) quantified by
measuring release of LDH, 24 hrs after the beginning of the exposure to BMAA. *
indicates significant toxicity, P < .05 (one-way ANOVA followed by the Bonferroni ttest).
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Table 1 Neuronal death induced by exposure of cortical cell cultures to
BMAA alone or in combination with another insult.
0
Insult

10

50

100 BMAA (µM)

% Neuronal Cell Death

Control

0±1

0±1

0±1

1±1

NMDA

6±2

6±2

7±2

26 ± 6*

Kainate

25 ± 5

23 ± 2

28 ± 4

30 ± 4

Fe

18 ± 3

19 ± 3

27 ± 4

33 ± 3*

BSO

25 ± 3

34 ± 6

33 ± 4

53 ± 6*

Amyloid-β

7±1

13 ± 1*

18 ± 2*

21 ± 2*

MPP+

8±2

23 ± 3*

46 ± 5*

49 ± 5*

24 ± 2

27 ± 3

24 ± 2

20 ± 2

19 ± 2

2*

21 ± 2

C-2 ceramide
Staurosporine

26 ± 2

18 ±

Concentrations used were: 5 µM NMDA; 30 µM kainate; 30 µM Fe, 250 µM BSO; 10 µM
amyloid-β (25–35); 10 µM MPP+; 50 µM C2-ceramide; 200 nM staurosporine.
Concentrations were chosen to induce low levels of neuronal death allowing
potentiation by BMAA to be observed. Data presented as mean ± SEM (n= 16–24)
quantified by measuring release of LDH, 24 hours after the beginning of the insult.
*indicates significant difference from control injury (insult with no BMAA present), P <
0.05 (one-way ANOVA followed by the Bonferroni t-test).

BMAA acts on the NMDA receptor
To determine the mechanism of BMAA effects on neuronal
death, we studied the toxicity induced by exposure to 3 mM BMAA.
This concentration of BMAA produces near complete neuronal death,
allowing for analysis of the toxic actions of BMAA without the
confounding effects of other insults. Previous studies have indicated
protection against BMAA toxicity by NMDA receptor antagonists (Ross
et al., 1987; Weiss et al., 1989). We found that the non-competitive
NMDA receptor antagonist MK-801 blocks about 50% of BMAA toxicity,
in contrast to its complete block of NMDA induced toxicity (Fig. 2a).
Exposure to either BMAA or NMDA for 1 hour induced increased
calcium influx, and the increase in each case was largely blocked by
MK-801 (88% block of BMAA induced 45Ca++ influx, 96% block of
NMDA induced 45Ca++ uptake) (Fig. 2b). These results indicate that
BMAA can cause death through the NMDA receptor, but since MK-801
only attenuates BMAA toxicity by 50% other factors are also involved.
To determine if the effect of BMAA is a direct effect on the NMDA
receptor, we performed whole cell patch-clamp electrophysiology on
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cultured cortical neurons. BMAA induced a concentration dependent
current, with a measurable current first observed at a concentration of
10 µM (Fig. 3a,b). The current was largely mediated by activation of
NMDA receptors as the competitive NMDA receptor antagonist Damino-5-phosphonovalerate (APV) blocked 94% of the current induced
by 3 mM BMAA (Fig. 3c,d) and provided complete blockade of the
current induced by 100 µM BMAA (data not shown).

Figure 2

(a) BMAA induced toxicity is partially blocked by the NMDA receptor

antagonist MK-801. Concentration used was: 10 µM MK801. Bars show % neuronal
cell death (mean ± s.e.m., n=12–16) quantified by measuring release of LDH, 24
hours after the beginning of the insult. * indicates significant difference from control
injury, P < 0.05 (Student’s t-test). BMAA mediated 45Ca++ uptake is blocked by MK801. (b) 45Ca++ uptake was measured during a 1 hour exposure to BMAA. Bars
show % control 45Ca++ uptake (mean ± s.e.m., n=16). * indicates significant
difference from BMAA or NMDA alone, P < 0.05 (Student’s t-test).

Neurobiology of Disease, Vol. 25, No. 2 (February 2007): pg. 360-366. DOI. This article is © Elseiver and permission has
been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article
to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

9

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Figure 3

BMAA has NMDA receptor agonist activity in CNS neurons. (a) Current

activated by BMAA at various concentrations in a cultured cortical neuron.
Concentrations used were: 10 – 3000 µM BMAA, 50 µM glycine,. (b) Concentration
dependence of BMAA-activated current. Note that concentrations in the low
micromolar range elicited measurable currents. (c) Current elicited by the application
of BMAA is blocked by the NMDA receptor antagonist APV. Concentrations used were:
3000 µM BMAA, 500 µM APV. (d) Bars indicate current (mean ± s.e.m.; n = 4)
activated by 3000 µM BMAA, in the absence and presence of 500 µM APV. * indicates
significant difference from BMAA alone, P < 0.05 (Mann-Whitney test).

BMAA toxicity involves the NMDA receptor, mGLuR5,
and oxidative stress
As in previous studies we found that blockade of NMDA
receptors provides significant protection against high concentration
BMAA toxicity (Ross et al., 1987; Weiss et al., 1989). However, as in
the previous studies, the protection was not complete, suggesting
additional mechanisms of BMAA toxicity. We found two other distinct
mechanisms are involved. The mGluR5 receptor antagonist 6-methyl2-[phenylethynyl]-pyridine (MPEP), and the free radical scavenger,
trolox, provided additional protection against BMAA toxicity beyond
that provided by MK-801 (Fig. 4a). Furthermore, the combination of
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these agents provided significantly greater protection then either
alone, suggesting that they were acting through distinct mechanisms.
Neither compound was protective against BMAA toxicity without MK801 present, likely because of the overwhelming toxicity induced by
BMAA activation of the NMDA receptor. No protection beyond that
caused by MK-801 was provided by the addition of the mGluR1
receptor antagonist 7-(hydroxyimino)cyclopropa[b] chromen-1Acarboxylate ethyl ester (CPCCOEt), the AMPA/kainate receptor
antagonist 6-cyano-7-nitro-quinoxaline-2,3-dione (CNQX), or the nonselective caspase inhibitor Z-Val-Ala-Asp-fluoromethylketone (ZVAD)
(data not shown). The protection afforded by trolox suggests that
BMAA induces oxidative stress. Therefore, we measured cellular
oxidative stress with the fluorescent dye dichlorofluorescein (DCF).
Exposure to 3 mM BMAA for 3 hours caused a significant increase in
oxidative stress which was not attenuated by MK-801 or MPEP, but
was blocked by trolox, with or without the presence of MK-801 (Fig.
4b).

Figure 4

(a) BMAA induced toxicity occurs through multiple mechanisms.

Concentrations used were: 10 µM MK-801, 50 µM MPEP, 100 µM trolox. Bars show %
neuronal cell death (mean ± s.e.m., n=24–28) quantified by measuring release of
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LDH, 24 hrs after the beginning of the insult. * indicates significant difference. (b)
BMAA induced oxidative stress is not attenuated by MK-801 or MPEP, but is blocked by
trolox. 5-(and –6)-carboxy-2’7’-dichlorodihydrofluorescein diacetate (10 µM) was
added to the cultures during a 3 hour exposure to BMAA. Bars show % control
fluorescence (mean ± s.e.m., n=24–28). * indicates significant difference, P < .05
(one-way ANOVA followed by the Bonferroni t-test).

Discussion
The present studies provide two important new findings. First,
they show that BMAA at concentrations as low as 10 µM can potentiate
neuronal injury induced by exposure to amyloid-β or MPP+. This is the
first evidence that BMAA at concentrations below the mM range can
enhance neuronal death in cortical cultures and illustrates an
important concept, the potential synergistic effects of environmental
toxins with underlying neurological conditions. Second, they show that
the mechanism of BMAA toxicity is threefold. It induces toxicity
through activation of NMDA and mGluR5 receptors, and it enhances
oxidative stress. The mechanism by which BMAA induces oxidative
stress was not determined, although it is clear that it is distinct from
NMDA and mGluR5 activation as BMAA induced oxidative stress was
not blocked by MK-801 or MPEP, and since trolox provided additional
protection beyond those agents. One possibility for BMAA-induced
oxidative stress is competition by BMAA with cystine at the
cystine/glutamate antiporter leading to decreased cystine uptake and
depletion of intracellular glutathione. Of interest MPEP in the presence
of MK-801 actually caused increased oxidative stress while still being
protective. Inhibition of group I mGluRs has been shown previously to
enhance oxidative stress (Sagara and Schubert, 1998). The protective
effect of MPEP must be through another mechanism, such as inhibition
of IP3 production and release of calcium from intracellular stores
(Nakamura et al., 2000).
The potentiation of injury by BMAA was selective for certain
insults. The type of death induced by the insult, apoptosis or necrosis,
does not appear to be the primary determining factor of the effects of
BMAA. Exposure to NMDA, Fe, and BSO all induce necrosis in this
culture system (Gwag et al., 1997; Lobner et al., 2003), and were
potentiated by BMAA. However, kainate also induces necrosis (Gwag et
al., 1997), but was unaffected by BMAA. Exposure to C2-ceramide and
staurosporine induce apoptosis (Lobner, 2000) and the injury was not
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enhanced by BMAA (Table 1). Amyloid-β and MPP+ toxicity have been
shown to induce neuronal death with features of both apoptosis and
necrosis (Pillot et al., 1999; Han et al., 2003) and the injury in each
case was enhanced by BMAA. Amyloid-β and MPP+ are of particular
importance in that amyloid-β toxicity is considered to be a model of
Alzheimer’s disease (Gotx et al., 2004) and MPP+ of Parkinson’s
disease (Gerlach and Riederer, 1996). The common point for BMAA
potentiation of these injuries may be that amyloid-β (Kwon et al.,
2004) and MPP+ (Johannessen et al., 1986) are known to induce
oxidative stress, as do exposure to NMDA, Fe, and BSO (Dugan et al.,
1995; Lobner et al., 2003).
The importance of the results of BMAA potentiation of specific
insults is that it shows that BMAA at concentrations 100 fold lower
than previously shown can enhance death of cortical neurons. A recent
report has shown that BMAA concentrations as low as 30 µM can cause
selective death of motor neurons (Rao et al., 2006). This study
suggests that in contrast to cortical neurons, motor neurons are highly
susceptible to BMAA toxicity even without an additional insult. The
change made in the current studies is that the effects of BMAA were
tested on low level injury induced by an additional insult as opposed to
only direct BMAA toxicity. The implication of these studies is that while
low level BMAA may not be the sole cause of neurological diseases, it
may be able to combine with underlying pathologies to either induce
expression of the disease or quicken its progression. An additional
factor to be considered is that the current studies represent effects of
BMAA over only a brief period of time (24 hours) in contrast to the
long-term exposure that appears to be involved in the development of
ALS/PDC. It seems likely that even lower concentrations of BMAA over
such long periods of exposure could enhance neuronal death. The
concentration of BMAA found in brain tissues of people who died of
ALS/PDC on Guam and Alzheimer’s disease in Canada was
approximately 6 µg/g (Cox et al., 2003). Unfortunately, an exact
correlation between the concentrations of BMAA used in these studies
and those found in the brain is not possible because it is not known
what concentration of BMAA occurs in the extracellular space
surrounding neurons in the brain following BMAA consumption.
Previous studies in mice have indicated that administration of BMAA
does not induce neurological deficits or neuronal death in vivo (Perry
et al., 1989; Cruz-Aguado et al., 2006). These results are not
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inconsistent with the current study. Our results suggest that BMAA
alone is unlikely to cause neurological deficits unless very high
concentrations are consumed, but that the combination of low levels of
BMAA consumption plus another insult may lead to the development of
neurological diseases. For example, while feeding mice low levels of
BMAA does not induce neurological deficits, feeding BMAA to mice
genetically altered to develop neurodegenerative diseases may alter
the onset or progression of the disease.
While it has been shown previously that BMAA activates the
NMDA receptor (Ross et al., 1987; Weiss and Choi, 1988; Brownson et
al., 2002), the electrophysiology studies involving BMAA provide a
couple of interesting insights. The BMAA-induced current occurred
even under conditions of saturating glycine, suggesting the effect is
due to an action at the NMDA binding site and not the glycine binding
site. The fact that BMAA induces a significant current even at low
concentrations, along with the protection of MK-801 against high
concentration BMAA toxicity, suggests that the potentiation of NMDA
toxicity is due to a direct action of BMAA on the NMDA receptor.
The importance of the multiple mechanisms of BMAA toxicity
shown in the current studies is that this may partially account for the
different types of neurological diseases that have been associated with
BMAA consumption. It is possible that the different actions of BMAA, in
association with varying underlying conditions, may lead to the
multiple disorders. Most neurodegenerative diseases appear to involve
NMDA receptor mediated excitotoxicity (Lipton, 2004) and oxidative
stress (Cui et al., 2004), and mGluR5 receptor activation has been
implicated in Parkinson’s disease (Marino et al., 2003). Therefore, it is
possible that BMAA may enhance the injury occurring during
neurodegenerative diseases, and in this way hasten the onset, or
increase the progression, of these diseases.
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